Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lev Pharmaceuticals has entered into an exclusive multi-year agreement with Biotest to sell all excess volumes of intermediate plasma products produced by The Sanquin Blood Supply Foundation during the manufacturing process of company's lead product candidate, Cinryze.
Subscribe to our email newsletter
Judson Cooper, Lev’s chairman, said: “Our agreement to sell intermediate plasma products is consistent with our strategic plan to monetize this valuable asset for Lev and provides us with additional operating flexibility as we prepare for the launch of our lead product candidate, Cinrzye.”